1.         Mazziotti G,Angeli A,Bilezikian JP,Canalis E,Giustina A, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab, 2006; 17: 144-9.

2.         Khosla S,Lufkin EG,Hodgson SF,Fitzpatrick LA,Melton LJ, 3rd, Epidemiology and clinical features of osteoporosis in young individuals. Bone, 1994; 15: 551-5.

3.         Alesci S,De Martino MU,Ilias I,Gold PW,Chrousos GP, Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation, 2005; 12: 1-19.

4.         Canalis E, Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab, 1996; 81: 3441-7.

5.         Orcel P, Prise en charge de l'osteoporose cortisonique. Presse Med, 2006; 35: 1571-7.

6.         Walsh LJ,Wong CA,Pringle M,Tattersfield AE, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Brit Med J, 1996; 313: 344-6.

7.         Compston J, Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol, 2010; 6: 82-88.

8.         Compston JE, Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep, 2007; 9: 78-84.

9.         Feldstein AC,Elmer PJ,Nichols GA,Herson M, Practice patterns in patient at risk for glucocorticoid-induced osteoporosis. Osteoporos Int, 2005; 16: 2168-2174.

10.       Curtis JR,Westfall AO,Allison JJ,Becker A,Casebeer L,Freeman A, et al., Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum, 2005; 52: 2485-2494.

11.       Duyvendak M,Naunton M,Atthobari J,van den Berg PB,Brouwers JR, Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Nederlands 2001-2005. Osteoporos Int, 2007; 18: 1429-1433.

12.       van Staa TP, The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int, 2006; 79: 129-37.

13.       van Staa TP,Leufkens HGM,Cooper C, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int, 2002; 13: 777-787.

14.       Steinbuch M,Youket TE,Cohen S, Oral glucocorticoid use is associated with an increased risk of fractures. Osteoporos Int, 2004; 15: 323-328.

15.       van Staa TP,Leufkens HG,Abenhaim L,Begaud B,Zhang B,Cooper C, Use of oral corticosteroids in the United Kingdom. QJM, 2000; 93: 105-111.

16.       Shaker JL,Lukert BP, Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am, 2005; 34: 341-56, viii-ix.

17.       Angeli A,Guglielmi G,Dovio A,Capelli G,de Feo D,Giannini S, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone, 2006; 39: 253-259.

18.       Cohen A,Shane E, Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int, 2003; 14: 617-630.

19.       Vestergaard P,Rejnmark L,Mosekilde L, Fracture risk associated with systemic and topical corticosteroids. J Intern Med, 2005; 257: 374-384.

20.       Van Staa TP,Leufkens HGM,Cooper C, Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res, 2001; 16: 581-588.

21.       van Staa TP,Leufkens HGM,Cooper C, Bone loss and inhaled glucocorticoids. N Engl J Med, 2002; 346: 533-535.

22.       Hubbard RB,Smith CJP,Smeeth L,Harrison TW,Tattersfield AE, Inhaled corticosteroids and hip fractures: a population-based case-control study. Am J Respir Crit Care Med, 2002; 166: 1563-1566.

23.       de Vries F,Pouwels S,Lammers JW,Leufkens HG,Bracke M,Cooper C, Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med, 2007; 261: 170-177.

24.       Mazziotti G,Giustina A,Canalis E,Bilezikian JP, Glucocorticoid-induced Osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metab, 2007; 51: 1404-1412.

25.       van Hogezand RA,Hamdy NA, Skeletal morbidity in inflammatory bowel disease. Scan J Gastroenterol, 2006; 243: S59-S64.

26.       Romas E, Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol, 2005; 19: 1065-1079.

27.       Lekamwasam S,Trivedi DP,Khaw KT, An association between respiratory function an bone mineral density in women from the general community: a cross sectional study. Osteoporos Int, 2002; 13: 710-715.

28.       Sin DD,Man JP,Man SF, The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med, 2003; 114: 10-14.

29.       Dykman TR,Gluck OS,Murphy WA,Hahn TJ,Hahn BH, Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum, 1985; 28: 361-8.

30.       Prentice A, Diet, nutrition and the prevention of osteoporosis. Public Health Nutr, 2004; 7: 227-243.

31.       Heaney RP, Effects of caffeine on bone and the calcium economy. Food and Chemical Toxicology, 2002; 40: 1263-1270.

32.       Heaney RP, Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr, 2003; 78: 912-919.

33.       Packard PT,Heaney RP, Medical Nutrition Therapy for Patients with Osteoporosis. J Am Diet Assoc, 1997; 97: 414-417.

34.       Michaelsson K,Lithell H,Vessby B,Melhus H, Serum retinol levels and the risk of fracture. N Engl J Med, 2003; 348: 287-94.

35.       Promislow JH,Goodman-Gruen D,Slymen DJ,Barrett-Connor E, Retinol intake and bone mineral density in the elderly: the Rancho Bernardo Study. J Bone Miner Res, 2002; 17: 1349-58.

36.       Feskanich D,Singh V,Willett WC,Colditz GA, Vitamin A Intake and Hip Fractures Among Postmenopausal Women. JAMA, 2002; 287: 47-54.

37.       Maggio D,Barabani M,Pierandrei M,Polidori MC,Catani M,Mecocci P, et al., Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab, 2003; 88: 1523-7.

38.       Lim LS,Harnack LJ,Lazovich D,Folsom AR, Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women's Health Study. Osteoporos Int, 2004; 15: 552-559.

39.       Hofbauer LC,Brueck CC,Singh SK,Dobnig H, Osteoporosis in patients with diabetes mellitus. J Bone Miner Res, 2007; 22: 1317-1328.

40.       Nicodemus KK,Folsom AR, Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care, 2001; 24: 1192-1197.

41.       Eastell R,Hannon RA,Cuzick J,Dowsett M,Clack G,Adams JE, Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-years results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res, 2006; 21: 1215-1223.

42.       Ebeling PR, Osteoporosis in men. N Engl J Med, 2008; 358: 1474-1482.

43.       Coates PS,Fernstrom JD,Fernstrom MH,Schauer PR,Greenspan SL, Gastric bypass surgery for a morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab, 2004; 89: 1061-1065.

44.       Bachelot A,Chakhtoura Z,Samara-Boustani D,Dulon J,Touraine P,Polak M, “Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol, 2010; 2010: 326275

45.       King JA,Wisniewski AB,Bankowski BJ,Carson KA,Zacur HA,Migeon CJ, Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2006; 91: 865-9.

46.       Cizza G,Ravn P,Chrousos GP,Gold PW, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab, 2001; 12: 198-203.

47.       Thompson JM,Modin GW,Arnaud CD,Lane NE, Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int, 1997; 61: 377-81.

48.       Varonos S,Ansell BM,Reeve J, Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int, 1987; 41: 75-8.

49.       Rizzato G,Tosi G,Mella C,Montemurro L,Zanni D,Sisti S, Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis, 1988; 5: 93-8.

50.       Rich GM,Mudge GH,Laffel GL,LeBoff MS, Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant, 1992; 11: 950-8.

51.       Shane E,Rivas MC,Silverberg SJ,Kim TS,Staron RB,Bilezikian JP, Osteoporosis after cardiac transplantation. Am J Med, 1993; 94: 257-64.

52.       Ruegsegger P,Medici TC,Anliker M, Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol, 1983; 25: 615-20.

53.       Russcher H,Smit P,van den Akker EL,van Rossum EF,Brinkmann AO,de Jong FH, Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab, 2005; 90: 804-810.

54.       van Rossum EF,Lamberts SW, Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res, 2004; 59: 333-357.

55.       Huizenga NA,Koper JW,De Lange P,Pols HA,Stolk RP,Burger H, et al., A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab, 1998; 83: 144-51.

56.       White PC,Mune T,Agarwal AK, 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev, 1997; 18: 135-56.

57.       Tomlinson JW,Walker EA,Bujalska IJ,Draper N,Lavery GG,Cooper MS, 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev, 2004; 25: 31-66.

58.       Tannin GM,Agarwal AK,Monder C,New MI,White PC, The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem, 1991; 266: 16653-8.

59.       Stewart PM,Krozowski ZS, 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm, 1999; 57: 249-324.

60.       Cooper MS,Walker EA,Bland R,Fraser WD,Hewison M,Stewart PM, Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone, 2000; 27: 375-81.

61.       Cooper MS,Bujalska I,Rabbit E,Walker EA,Bland R,Sheppard MC, Modulation of 11beta-hydroxysteroid dehydrogenase isoenzymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Mineral Res, 2001; 16: 1037-1044.

62.       Williams LJ,Lyons V,MacLeod I,Rajan V,Darlington GJ,Poli V, C/EBP regulates hepatic transcription of 11beta-hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem, 2000; 275: 30232-30239.

63.       Escher G,Galli I,Vishwanath BS,Frey BM,Frey FJ, Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J Exp Med, 1997; 186: 189-98.

64.       Cooper MS,Rabbit EH,Goddard PE,Bartlett WA,Hewison M,Stewart PM, Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Mineral Res, 2002; 17: 979-986.

65.       Katagiri T,Takahashi N, Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis, 2002; 8: 147-59.

66.       Ehrlich PJ,Lanyon LE, Mechanical strain and bone cell function: a review. Osteoporos Int, 2002; 13: 688-700.

67.       Laan RF,Buijs WC,van Erning LJ,Lemmens JA,Corstens FH,Ruijs SH, et al., Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int, 1993; 52: 5-9.

68.       Reid IR,Heap SW, Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med, 1990; 150: 2545-8.

69.       Reid IR,Evans MC,Stapleton J, Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res, 1992; 7: 1221-5.

70.       Reid IR,Evans MC,Wattie DJ,Ames R,Cundy TF, Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int, 1992; 2: 103-5.

71.       Sambrook P,Birmingham J,Kempler S,Kelly P,Eberl S,Pocock N, et al., Corticosteroid effects on proximal femur bone loss. J Bone Miner Res, 1990; 5: 1211-6.

72.       Lane NE, An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am, 2001; 27: 235-253.

73.       Saag KG, Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am, 2003; 32: 135-157.

74.       Adinoff AD,Hollister JR, Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med, 1983; 309: 265-8.

75.       Dempster DW, Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res, 1989; 4: 137-41.

76.       Hahn TJ,Boisseau VC,Avioli LV, Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab, 1974; 39: 274-82.

77.       Aaron JE,Francis RM,Peacock M,Makins NB, Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop, 1989: 294-305.

78.       Bamberger CM,Schulte HM,Chrousos GP, Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev, 1996; 17: 245-61.

79.       Vottero A,Chrousos GP, Glucocorticoid Receptor beta: View I. Trends Endocrinol Metab, 1999; 10: 333-338.

80.       Beavan S,Horner A,Bord S,Ireland D,Compston J, Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res, 2001; 16: 1496-504.

81.       Masera RG,Dovio A,Sartori ML,Racca S,Angeli A, Interleukin-6 upregulates glucocorticoid receptor numbers in human osteoblast-like cells. Z Rheumatol, 2000; 59 Suppl 2: II/103-7.

82.       Dovio A,Masera RG,Sartori ML,Racca S,Angeli A, Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int, 2001; 69: 293-8.

83.       Dovio A,Sartori ML,Masera RG,Ceoloni B,Reimondo G,Prolo P, et al., Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. J Endocrinol, 2003; 177: 109-17.

84.       Angeli A,Dovio A,Sartori ML,Masera RG,Ceoloni B,Prolo P, et al., Interactions between glucocorticoids and cytokines in the bone microenvironment. Ann N Y Acad Sci, 2002; 966: 97-107.

85.       Weinstein RS,Jilka RL,Michael Parfitt A,Manolagas SC, Inhibition of Osteoblastogenesis and Promotion of Apoptosis of Osteoblasts and Osteocytes by Glucocorticoids . Potential Mechanisms of Their Deleterious Effects on Bone. J Clin Invest, 1998; 102: 274-282.

86.       O'Brien CA,Jia D,Plotkin LI,Bellido T,Powers CC,Stewart SA, et al., Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology, 2004; 145: 1835-1841.

87.       Manolagas SC, Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev, 2000; 21: 115-37.

88.       Stromstedt PE,Poellinger L,Gustafsson JA,Carlstedt-Duke J, The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol Cell Biol, 1991; 11: 3379-83.

89.       Heinrichs AA,Bortell R,Rahman S,Stein JL,Alnemri ES,Litwack G, et al., Identification of multiple glucocorticoid receptor binding sites in the rat osteocalcin gene promoter. Biochemistry, 1993; 32: 11436-44.

90.       Jonat C,Rahmsdorf HJ,Park KK,Cato AC,Gebel S,Ponta H, et al., Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell, 1990; 62: 1189-204.

91.       Morrison N,Eisman J, Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res, 1993; 8: 969-75.

92.       Raisz LG, Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest, 2005; 115: 3318-25.

93.       Ohnaka K,Tanabe M,Kawate H,Nawata H,Takayanagi R, Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun, 2005; 329: 177-81.

94.       Delany AM,Gabbitas BY,Canalis E, Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem, 1995; 57: 488-94.

95.       Delany AM,Jeffrey JJ,Rydziel S,Canalis E, Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem, 1995; 270: 26607-12.

96.       Roodman GD, Cell biology of the osteoclast. Exp Hematol, 1999; 27: 1229-41.

97.       Raisz LG,Trummel CL,Wener JA,Simmons H, Effect of glucocorticoids on bone resorption in tissue culture. Endocrinology, 1972; 90: 961-7.

98.       Tobias J,Chambers TJ, Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. Endocrinology, 1989; 125: 1290-5.

99.       Gronowicz G,McCarthy MB,Raisz LG, Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro. J Bone Miner Res, 1990; 5: 1223-30.

100.     Lowe C,Gray DH,Reid IR, Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria. Calcif Tissue Int, 1992; 50: 189-92.

101.     Conaway HH,Grigorie D,Lerner UH, Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones. J Endocrinol, 1997; 155: 513-21.

102.     Defranco DJ,Lian JB,Glowacki J, Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats. Endocrinology, 1992; 131: 114-21.

103.     Bar-Shavit Z,Kahn AJ,Pegg LE,Stone KR,Teitelbaum SL, Glucocorticoids modulate macrophage surface oligosaccharides and their bone binding activity. J Clin Invest, 1984; 73: 1277-83.

104.     Teitelbaum SL,Bar-Shavit Z,Fallon MD,Imbimbo C,Malone JD,Kahn AJ, Glucocorticoids and bone resorption. Adv Exp Med Biol, 1984; 171: 121-9.

105.     Liu YZ,Dvornyk V,Lu Y,Shen H,Lappe JM,Recker RR, et al., A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes. J Biol Chem, 2005; 280: 29011-6.

106.     Takuma A,Kaneda T,Sato T,Ninomiya S,Kumegawa M,Hakeda Y, Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem, 2003; 278: 44667-74.

107.     Heymann D,Guicheux J,Gouin F,Passuti N,Daculsi G, Cytokines, growth factors and osteoclasts. Cytokine, 1998; 10: 155-68.

108.     Rifas L, Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcif Tissue Int, 1999; 64: 1-7.

109.     Horowitz MC,Xi Y,Wilson K,Kacena MA, Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev, 2001; 12: 9-18.

110.     Hofbauer LC,Heufelder AE, Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab, 2000; 85: 2355-63.

111.     Pfeilschifter J,Seyedin SM,Mundy GR, Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J Clin Invest, 1988; 82: 680-5.

112.     Ake Y,Saegusa Y,Matsubara T,Mizuno K, Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci, 1994; 40: 125-37.

113.     Vidal NO,Brandstrom H,Jonsson KB,Ohlsson C, Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol, 1998; 159: 191-195.

114.     Bornefalk E,Dahlen I,Johannsson G,Ljunggren O,Ohlsson C, Serum levels of osteoprotegerin: effects of glucocorticoids and growth hormone. Bone, 1998; 23: S486.

115.     Hofbauer LC,Gori F,Riggs BL,Lacey DL,Dunstan CR,Spelsberg TC, et al., Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology, 1999; 140: 4382-9.

116.     Hock JM,Centrella M,Canalis E, Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology, 1988; 122: 254-60.

117.     Canalis E,Rydziel S,Delany AM,Varghese S,Jeffrey JJ, Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology, 1995; 136: 1348-54.

118.     Delany AM,Durant D,Canalis E, Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol, 2001; 15: 1781-9.

119.     Bennett A,Chen T,Feldman D,Hintz RL,Rosenfeld RG, Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids. Endocrinology, 1984; 115: 1577-83.

120.     Rydziel S,Canalis E, Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures. Endocrinology, 1995; 136: 4254-60.

121.     Rechler MM, Insulin-like growth factor binding proteins. Vitam Horm, 1993; 47: 1-114.

122.     Okazaki R,Riggs BL,Conover CA, Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. Endocrinology, 1994; 134: 126-32.

123.     Gabbitas B,Pash JM,Delany AM,Canalis E, Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem, 1996; 271: 9033-8.

124.     Andress DL,Birnbaum RS, Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem, 1992; 267: 22467-72.

125.     Mehls O,Himmele R,Homme M,Kiepe D,Klaus G, The interaction of glucocorticoids with the growth hormone-insulin-like growth factor axis and its effects on growth plate chondrocytes and bone cells. J Pediatr Endocrinol Metab, 2001; 14: 1475-1482.

126.     Pereira RC,Blanquaert F,Canalis E, Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology, 1999; 140: 228-32.

127.     Canalis E,Pash J,Varghese S, Skeletal growth factors. Crit Rev Eukaryot Gene Expr, 1993; 3: 155-66.

128.     Gurlek A,Kumar R, Regulation of osteoblast growth by interactions between transforming growth factor-beta and 1alpha,25-dihydroxyvitamin D3. Crit Rev Eukaryot Gene Expr, 2001; 11: 299-317.

129.     Alliston T,Choy L,Ducy P,Karsenty G,Derynck R, TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. Embo J, 2001; 20: 2254-72.

130.     Centrella M,McCarthy TL,Canalis E, Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol, 1991; 11: 4490-6.

131.     Oursler MJ,Riggs BL,Spelsberg TC, Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells. Endocrinology, 1993; 133: 2187-96.

132.     Fuller K,Owens J,Chambers TJ, The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Commun, 1995; 212: 334-40.

133.     Sato T,Hakeda Y,Yamaguchi Y,Mano H,Tezuka K,Matsumoto K, et al., Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol, 1995; 164: 197-204.

134.     Grano M,Galimi F,Zambonin G,Colucci S,Cottone E,Zallone AZ, et al., Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A, 1996; 93: 7644-8.

135.     Ferracini R,Di Renzo MF,Scotlandi K,Baldini N,Olivero M,Lollini P, et al., The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene, 1995; 10: 739-49.

136.     Hock JM,Canalis E, Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology, 1994; 134: 1423-8.

137.     Raines EW,Lane TF,Iruela-Arispe ML,Ross R,Sage EH, The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A, 1992; 89: 1281-5.

138.     Ng KW,Manji SS,Young MF,Findlay DM, Opposing influences of glucocorticoid and retinoic acid on transcriptional control in preosteoblasts. Mol Endocrinol, 1989; 3: 2079-85.

139.     Raisz LG, Prostaglandins and bone: physiology and pathophysiology. Osteoarthr Cartilage, 1999; 7: 419-21.

140.     Chyun YS,Raisz LG, Stimulation of bone formation by prostaglandin E2. Prostaglandins, 1984; 27: 97-103.

141.     Canalis E, The hormonal and local regulation of bone formation. Endocr Rev, 1983; 4: 62-77.

142.     Raisz LG,Dietrich JW,Canalis EM, Factors influencing bone formation in organ culture. Isr J Med Sci, 1976; 12: 108-14.

143.     Raisz LG,Fall PM, Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: interaction with cortisol. Endocrinology, 1990; 126: 1654-9.

144.     Hughes-Fulford M, Prostaglandin regulation of gene expression and growth in normal and malignant tissues. Adv Exp Med Biol, 1997; 400A: 269-78.

145.     Hughes-Fulford M,Appel R,Kumegawa M,Schmidt J, Effect of dexamethasone on proliferating osteoblasts: inhibition of prostaglandin E2 synthesis, DNA synthesis, and alterations in actin cytoskeleton. Exp Cell Res, 1992; 203: 150-6.

146.     Kimberg DV,Baerg RD,Gershon E,Graudusius RT, Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest, 1971; 50: 1309-21.

147.     Fuller K,Chambers TJ, Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J Bone Miner Res, 1989; 4: 209-15.

148.     Klein DC,Raisz LG, Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology, 1970; 86: 1436-40.

149.     Wajchenberg BL,Pereira VG,Kieffer J,Ursic S, Effect of dexamethasone on calcium metabolism and 47Ca kinetics in normal subjects. Acta Endocrinol (Copenh), 1969; 61: 173-92.

150.     Morris HA,Need AG,O'Loughlin PD,Horowitz M,Bridges A,Nordin BE, Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int, 1990; 46: 305-8.

151.     Binder HJ, Effect of dexamethasone on electrolyte transport in the large intestine of the rat. Gastroenterology, 1978; 75: 212-7.

152.     Sjoberg HE, Retention of orally administered 47-calcium in man under normal and diseased conditions studied with a whole-body counter technique. Acta Med Scand Suppl, 1970; 509: 1-28.

153.     Lee DB, Unanticipated stimulatory action of glucocorticoids on epithelial calcium absorption. Effect of dexamethasone on rat distal colon. J Clin Invest, 1983; 71: 322-8.

154.     Hahn TJ,Halstead LR,Strates B,Imbimbo B,Baran DT, Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man. Calcif Tissue Int, 1980; 31: 109-15.

155.     Lekkerkerker JF,Van Woudenberg F,Doorenbos H, Influence of low dose of steroid therapy on calcium absorption. Acta Endocrinol (Copenh), 1972; 69: 488-96.

156.     Aloia JF,Semla HM,Yeh JK, Discordant effects of glucocorticoids on active and passive transport of calcium in the rat duodenum. Calcif Tissue Int, 1984; 36: 327-31.

157.     Shultz TD,Bollman S,Kumar R, Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: evidence for dissociation of calcium absorption from brush border vesicle uptake. Proc Natl Acad Sci U S A, 1982; 79: 3542-6.

158.     Kimura S,Rasmussen H, Adrenal glucocorticoids, adenine nucleotide translocation, and mitochondrial calcium accumulation. J Biol Chem, 1977; 252: 1217-25.

159.     Suzuki Y,Ichikawa Y,Saito E,Homma M, Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism, 1983; 32: 151-6.

160.     Nielsen HK,Thomsen K,Eriksen EF,Charles P,Storm T,Mosekilde L, The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner, 1988; 4: 105-13.

161.     Adams JS,Wahl TO,Lukert BP, Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism, 1981; 30: 217-21.

162.     Au WY, Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture. Science, 1976; 193: 1015-7.

163.     Cosman F,Nieves J,Herbert J,Shen V,Lindsay R, High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res, 1994; 9: 1097-105.

164.     Freiberg JM,Kinsella J,Sacktor B, Glucocorticoids increase the Na+-H+ exchange and decrease the Na+ gradient-dependent phosphate-uptake systems in renal brush border membrane vesicles. Proc Natl Acad Sci U S A, 1982; 79: 4932-6.

165.     Heersche JN,Jez DH,Aubin J,Sodek J, Regulation of hormone responsiveness of bone in vitro by corticosteroids, PTH, PGE2, and calcitonin., in Hormonal control of calcium metabolism, R.V. Talmage, D.V. Cohn, and J.L. Mathews, Editors. 1981, Excerpta Medica: Amsterdam. p. 157-162.

166.     Fucik RF,Kukreja SC,Hargis GK,Bowser EN,Henderson WJ,Williams GA, Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab, 1975; 40: 152-5.

167.     Lukert BP,Adams JS, Calcium and phosphorus homeostasis in man. Effect of corticosteroids. Arch Intern Med, 1976; 136: 1249-53.

168.     Bonadonna S,Burattin A,Nuzzo M,Bugari G,Rosei EA,Valle D, et al., Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol, 2005; 152: 199-205.

169.     Lukert BP,Stanbury SW,Mawer EB, Vitamin D and intestinal transport of calcium: effects of prednisolone. Endocrinology, 1973; 93: 718-22.

170.     Hahn TJ,Halstead LR,Haddad JG, Jr., Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med, 1977; 90: 399-404.

171.     Chesney RW,Mazess RB,Hamstra AJ,DeLuca HF,O'Reagan S, Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids. Lancet, 1978; 2: 1123-5.

172.     Zerwekh JE,Emkey RD,Harris ED, Jr., Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism. Arthritis Rheum, 1984; 27: 1050-2.

173.     Seeman E,Kumar R,Hunder GG,Scott M,Heath H, 3rd,Riggs BL, Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. J Clin Invest, 1980; 66: 664-9.

174.     Colette C,Monnier L,Pares Herbute N,Blotman F,Mirouze J, Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. Horm Metab Res, 1987; 19: 335-8.

175.     Hahn TJ,Halstead LR,Teitelbaum SL,Hahn BH, Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest, 1979; 64: 655-65.

176.     Klein RG,Arnaud SB,Gallagher JC,Deluca HF,Riggs BL, Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest, 1977; 60: 253-9.

177.     Luton JP,Thieblot P,Valcke JC,Mahoudeau JA,Bricaire H, Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab, 1977; 45: 488-95.

178.     Sakakura M,Takebe K,Nakagawa S, Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab, 1975; 40: 774-9.

179.     Hsueh AJ,Erickson GF, Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids, 1978; 32: 639-48.

180.     Swift AD,Crighton DB, The effects of certain steroid hormones on the activity of ovine hypothalamic luteinizing hormone-releasing hormone (LH-RH)-degrading enzymes. FEBS Lett, 1979; 100: 110-2.

181.     Dubey AK,Plant TM, A suppression of gonadotropin secretion by cortisol in castrated male rhesus monkeys (Macaca mulatta) mediated by the interruption of hypothalamic gonadotropin-releasing hormone release. Biol Reprod, 1985; 33: 423-31.

182.     Sapolsky RM, Stress-induced suppression of testicular function in the wild baboon: role of glucocorticoids. Endocrinology, 1985; 116: 2273-8.

183.     Crilly R,Cawood M,Marshall DH,Nordin BE, Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med, 1978; 71: 733-6.

184.     Montecucco C,Caporali R,Caprotti P,Caprotti M,Notario A, Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol, 1992; 19: 1895-900.

185.     MacAdams MR,White RH,Chipps BE, Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med, 1986; 104: 648-51.

186.     Urban RJ,Veldhuis JD, Endocrine control of steroidogenesis in granulosa cells. Oxf Rev Reprod Biol, 1992; 14: 225-62.

187.     Buyon JP,Dooley MA,Meyer WR,Petri M,Licciardi F, Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo- or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum, 1997; 40: 1548-9.

188.     Goulding A,Gold E, Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol. Endocrinology, 1988; 122: 482-7.

189.     Ohlsson C,Bengtsson BA,Isaksson OG,Andreassen TT,Slootweg MC, Growth hormone and bone. Endocr Rev, 1998; 19: 55-79.

190.     Giustina A,Bussi AR,Jacobello C,Wehrenberg WB, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab, 1995; 80: 122-9.

191.     Manelli F,Carpinteri R,Bossoni S,Burattin A,Bonadonna S,Agabiti Rosei E, et al., Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res, 2002; 30: 174-83.

192.     King AP,Tseng MJ,Logsdon CD,Billestrup N,Carter-Su C, Distinct cytoplasmic domains of the growth hormone receptor are required for glucocorticoid- and phorbol ester-induced decreases in growth hormone (GH) binding. These domains are different from that reported for GH-induced receptor internalization. J Biol Chem, 1996; 271: 18088-94.

193.     Pratt WB,Aronow L, The effect of glucocorticoids on protein and nucleic acid synthesis in mouse fibroblasts growing in vitro. J Biol Chem, 1966; 241: 5244-50.

194.     Leibovich SJ,Ross R, The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol, 1975; 78: 71-100.

195.     Afifi AK,Bergman RA,Harvey JC, Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J, 1968; 123: 158-73.

196.     Pleasure DE,Walsh GO,Engel WK, Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol, 1970; 22: 118-25.

197.     Rebuffe-Scrive M,Krotkiewski M,Elfverson J,Bjorntorp P, Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab, 1988; 67: 1122-8.

198.     Wang L,Luo GJ,Wang JJ,Hasselgren PO, Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes. Shock, 1998; 10: 298-306.

199.     Auclair D,Garrel DR,Chaouki Zerouala A,Ferland LH, Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol, 1997; 272: C1007-16.

200.     Danneskiold-Samsoe B,Grimby G, The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis. Clin Sci (Lond), 1986; 71: 693-701.

201.     Askari A,Vignos PJ, Jr.,Moskowitz RW, Steroid myopathy in connective tissue disease. Am J Med, 1976; 61: 485-92.

202.     Gonnelli S,Rottoli P,Cepollaro C,Pondrelli C,Cappiello V,Vagliasindi M, et al., Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int, 1997; 61: 382-385.

203.     Adler RA,Hochberg MC, Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs. Arch Intern Med, 2003; 163: 2619-2624.

204.     Anonymous, Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med, 1993; 94: 646-50.

205.     Anonymous, Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001; 285: 785-795.

206.     Anonymous, Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum, 2001; 44: 1496-503.

207.     Eastell R,Reid DM,Compston J,Cooper C,Fogelman I,Francis RM, et al., A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med, 1998; 244: 271-92.

208.     Lukert BP,Higgins JC,Stoskopf MM, Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab, 1986; 62: 1056-8.

209.     Ekenstam E,Stalenheim G,Hallgren R, The acute effect of high dose corticosteroid treatment on serum osteocalcin. Metabolism, 1988; 37: 141-4.

210.     Prummel MF,Wiersinga WM,Lips P,Sanders GT,Sauerwein HP, The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab, 1991; 72: 382-6.

211.     Reid IR,Chapman GE,Fraser TR,Davies AD,Surus AS,Meyer J, et al., Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab, 1986; 62: 379-83.

212.     Hall GM,Spector TD,Delmas PD, Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum, 1995; 38: 902-6.

213.     Reeve J,Loftus J,Hesp R,Ansell BM,Wright DJ,Woo PM, Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol, 1993; 20: 1189-95.

214.     Ton FN,Gunawardene SC,Lee H,Neer RM, Effects of low-dose prednisone on bone metabolism. J Bone Miner Res, 2005; 20: 464-470.

215.     Lems WF,Gerrits MI,Jacobs JW,van Vugt RM,van Rijn HJ,Bijlsma JW, Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis, 1996; 55: 288-93.

216.     Gennari C,Imbimbo B,Montagnani M,Bernini M,Nardi P,Avioli LV, Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int, 1984; 36: 245-52.

217.     Baran DT,Faulkner KG,Genant HK,Miller PD,Pacifici R, Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif Tissue Int, 1997; 61: 433-440.

218.     Guglielmi G,Lang TF, Quantitative computed tomography. Semin Musculoskelet Radiol, 2002; 6: 219-227.

219.     Hui SL,Slemenda CW,Johnston CC, Jr., Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med, 1989; 111: 355-61.

220.     Blake GM,Fogelman I, Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am, 1998; 27: 267-88.

221.     Finkelstein JS,Cleary RL,Butler JP,Antonelli R,Mitlak BH,Deraska DJ, et al., A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab, 1994; 78: 724-30.

222.     Van Staa TP,Laan RF,Barton IP,Cohen S,Reid DM,Cooper C, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum, 2003; 48: 3224-3229.

223.     Kanis JA,Johannsson H,Oden A, A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004; 19: 893-899.

224.     Kanis JA,Torgerson D,Cooper C, Comparison of the European and USA practice guidelines for Osteoporosis. Trends Endocrinol Metab, 2000; 11: 28-32.

225.     Adler GS,Shatto A, Screening for osteoporosis and colon cancer under Medicare. Health Care Financ Rev, 2002; 23: 189-200.

226.     Kanis JA,Johansson H,Oden A,McCloskey EV, Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int, 2011; DOI 10.1007/s00198-010-1524-7.

227.     Grossman JM,Gordon R,Ranganath VK,Deal C,Caplan L,Chen W, et al., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken), 2010; 62: 1515-1526.

228.     Devogelaer JP,Goemaere S,Boonen S,Body JJ,Kaufman JM,Reginster JY, et al., Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int, 2006; 17: 8-19.

229.     Gluck OS,Murphy WA,Hahn TJ,Hahn B, Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum, 1981; 24: 892-8.

230.     Martinati LC,Bertoldo F,Gasperi E,Fortunati P,Lo Cascio V,Boner AL, Longitudinal evaluation of bone mass in asthmatic children treated with inhaled beclomethasone dipropionate or cromolyn sodium. Allergy, 1998; 53: 705-8.

231.     Frediani B,Falsetti P,Bisogno S,Baldi F,Acciai C,Filippou G, et al., Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol, 2004; 31: 1083-1087.

232.     Nielsen HK,Charles P,Mosekilde L, The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab, 1988; 67: 1025-1030.

233.     Richy F,Bousquet J,Ehrlich GE,Meunier PJ,Israel E,Morii H, et al., Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int, 2003; 14: 179-190.

234.     Bootsma GP,Dekhuijzen PN,Festen J,Mulder PG,Swinkels LM,van Herwaarden CL, Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med, 1996; 153: 924-30.

235.     Luengo M,del Rio L,Pons F,Picado C, Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J, 1997; 10: 2110-3.

236.     Ebeling PR,Erbas B,Hopper JL,Wark JD,Rubinfeld AR, Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res, 1998; 13: 1283-9.

237.     Aris R,Donohue JF,Ontjes D, Inhaled corticosteroids and fracture risk: having our cake and eating it too. Chest, 2005; 127: 5-7.

238.     van Staa TP,Bishop N,Leufkens HG,Cooper C, Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int, 2004; 15: 785-791.

239.     Pennisi P,Trombetti A,Rizzoli R, Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res, 2006; 443: 39-47.

240.     Boonen S, Corticosteroid-induced osteoporosis, in 20th IOF Advanced training course on osteoporosis. 2011, IOF: Geneva. 213-223.

241.     Prestwood KM,Raisz LG, Prevention and treatment of osteoporosis. Clin Cornerstone, 2002; 4: 31-41.

242.     Buckley LM,Leib ES,Cartularo KS,Vacek PM,Cooper SM, Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 1996; 125: 961-8.

243.     Adachi JD,Bensen WG,Bianchi F,Cividino A,Pillersdorf S,Sebaldt RJ, et al., Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol, 1996; 23: 995-1000.

244.     Reginster JY,Kuntz D,Verdickt W,Wouters M,Guillevin L,Menkes CJ, et al., Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int, 1999; 9: 75-81.

245.     Amin S,LaValley MP,Simms RW,Felson DT, The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum, 1999; 42: 1740-51.

246.     Homik J,Suarez-Almazor ME,Shea B,Cranney A,Wells G,Tugwell P, Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev, 2000: CD000952.

247.     Dechant KL,Goa KL, Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drugs Aging, 1994; 5: 300-317.

248.     Adverse Drug Reactions Advisory Committee A, Calcitriol and hypercalcaemia. Aust Adv Drug React Bull, 1997; 16: 2.

249.     LaCroix AZ,Wienpahl J,White LR,Wallace RB,Scherr PA,George LK, et al., Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med, 1990; 322: 286-90.

250.     Felson DT,Sloutskis D,Anderson JJ,Anthony JM,Kiel DP, Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA, 1991; 265: 370-3.

251.     Cauley JA,Cummings SR,Seeley DG,Black D,Browner W,Kuller LH, et al., Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med, 1993; 118: 666-73.

252.     Rodan GA,Fleisch HA, Bisphosphonates: mechanisms of action. J Clin Invest, 1996; 97: 2692-6.

253.     Sambrook PN, How to prevent steroid induced osteoporosis. Ann Rheum Dis, 2005; 64: 176-8.

254.     Adachi JD,Saag KG,Delmas PD,Liberman UA,Emkey RD,Seeman E, et al., Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum, 2001; 44: 202-11.

255.     de Nijs RN,Jacobs JW,Lems WF,Laan RF,Algra A,Huisman AM, et al., Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med, 2006; 355: 675-84.

256.     Shane E,Addesso V,Namerow PB,McMahon DJ,Lo SH,Staron RB, et al., Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med, 2004; 350: 767-776.

257.     Reid DM,Hughes RA,Laan RF,Sacco-Gibson NA,Wenderoth DH,Adami S, et al., Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res, 2000; 15: 1006-13.

258.     Adachi JD,Bensen WG,Brown J,Hanley D,Hodsman A,Josse R, et al., Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med, 1997; 337: 382-7.

259.     Struys A,Snelder AA,Mulder H, Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med, 1995; 99: 235-42.

260.     Reid IR,Heap SW,King AR,Ibbertson HK, Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet, 1988; 2: 1144.

261.     Boutsen Y,Jamart J,Esselinckx W,Devogelaer JP, Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res, 2001; 16: 104-12.

262.     Herrala J,Puolijoki H,Liippo K,Raitio M,Impivaara O,Tala E, et al., Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone, 1998; 22: 577-82.

263.     Reid IR,Brown JP,Burckhardt P,Horowitz Z,Richardson P,Trechsel U, et al., Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med, 2002; 346: 653-661.

264.     Reid IR, Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol, 2003; 15: 458-63.

265.     Theriault RL, Zoledronic acid (Zometa) use in bone disease. Expert Rev Anticancer Ther, 2003; 3: 157-66.

266.     Biskobing DM, Novel therapies for osteoporosis. Expert Opin Investig Drugs, 2003; 12: 611-21.

267.     Biskobing DM,Novy AM,Downs R, Jr., Novel therapeutic options for osteoporosis. Curr Opin Rheumatol, 2002; 14: 447-52.

268.     Doggrell SA, Zoledronate once-yearly increases bone mineral density--implications for osteoporosis. Expert Opin Pharmacother, 2002; 3: 1007-9.

269.     Reid DM,Devogelaer JP,Saag K,Roux C,Lau CS,Reginster JY, et al., Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2009; 373: 1253-1263.

270.     Miller PD,McClung MR,Macovei L, Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 2005; 20: 1315-1322.

271.     Devogelaer JP, New perspectives in the management of glucocorticoid-induced osteoporosis. European Musculuskeletal Review 2010; 5: 40-43.

272.     Luengo M,Pons F,Martinez de Osaba MJ,Picado C, Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax, 1994; 49: 1099-102.

273.     Montemurro L,Schiraldi G,Fraioli P,Tosi G,Riboldi A,Rizzato G, Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int, 1991; 49: 71-6.

274.     Cranney A,Tugwell P,Zytaruk N,Robinson V,Weaver B,Shea B, et al., Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev, 2002; 23: 540-551.

275.     Lyritis GP,Tsakalakos N,Magiasis B,Karachalios T,Yiatzides A,Tsekoura M, Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int, 1991; 49: 369-72.

276.     Lems WF,Jacobs WG,Bijlsma JW,Croone A,Haanen HC,Houben HH, et al., Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int, 1997; 7: 575-82.

277.     Lems WF,Jacobs JW,Bijlsma JW,van Veen GJ,Houben HH,Haanen HC, et al., Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis, 1997; 56: 357-63.

278.     Adami S,Fossaluzza V,Rossini M,Bertoldo F,Gatti D,Zamberlan N, et al., The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner, 1991; 15: 73-81.

279.     Grecu EO,Weinshelbaum A,Simmons R, Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int, 1990; 46: 294-9.

280.     Lane NE,Sanchez S,Modin GW,Genant HK,Pierini E,Arnaud CD, Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res, 2000; 15: 944-51.

281.     Lane NE,Sanchez S,Modin GW,Genant HK,Pierini E,Arnaud CD, Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest, 1998; 102: 1627-33.

282.     Devogelaer JP,Adler RA,Recknor C,See K,Warner MR,Wong M, et al., Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol, 2010; 37: 141-148.

283.     Saag KG,Zanchetta JR,Devogelaer JP,Adler RA,Eastell R,See K, et al., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum, 2009; 60: 3346-3355.

284.     Summey BT,Yosipovitch G, Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol, 2006; 142: 82-90.

285.     Hodsman AB,Bauer DC,Dempster D, Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev, 2005; 26: 688-703.

286.     Black DM,Greenspan SL,Ensrud KE, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 2003; 349: 1207-1215.

287.     Rittmaster RS,Bolognese M,Ettinger MP, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab, 2000; 85: 2129-2134.

288.     Lukert BP,Johnson BE,Robinson RG, Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res, 1992; 7: 1063-9.

289.     Hall GM,Daniels M,Doyle DV,Spector TD, Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum, 1994; 37: 1499-505.

290.     Rossouw JE,Anderson GL,Prentice RL,LaCroix AZ,Kooperberg C,Stefanick ML, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288: 321-33.

291.     Reid IR,Wattie DJ,Evans MC,Stapleton JP, Testosterone therapy in glucocorticoid-treated men. Arch Intern Med, 1996; 156: 1173-7.

292.     Gruenewald DA,Matsumoto AM, Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks. J Am Geriatr Soc, 2003; 51: 101-115.

293.     Oettel M, The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften, 2004; 91: 66-76.

294.     Hafez B,Hafez ES, Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology. Arch Androl, 2004; 50: 45-68.

295.     Rhoden EL,Morgentaler A, Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med, 2004; 350: 482-92.

296.     Fritz PC,Ward WE,Atkinson SA,Tenenbaum HC, Tamoxifen attenuates the effects of exogenous glucocorticoid on bone formation and growth in piglets. Endocrinology, 1998; 139: 3399-403.

297.     Delmas PD,Bjarnason NH,Mitlak BH,Ravoux AC,Shah AS,Huster WJ, et al., Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med, 1997; 337: 1641-7.

298.     Ettinger B,Black DM,Mitlak BH,Knickerbocker RK,Nickelsen T,Genant HK, et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999; 282: 637-45.

299.     Dore RK,Cohen SB,Lane NE,Palmer W,Shergy W,Zhou L, et al., Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis, 2010; 69: 872-875.

300.     Resche-Rigon M,Gronemeyer H, Therapeutic potential of selective modulators of nuclear receptor action. Curr Opin Chem Biol, 1998; 2: 501-7.

301.     Leong GM,Mercado-Asis LB,Reynolds JC,Hill SC,Oldfield EH,Chrousos GP, The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab, 1996; 81: 1905-11.

302.     Catargi B,Tabarin A,Basse-Cathalinat B,Ducassou D,Roger P, [Development of bone mineral density after cure of Cushing's syndrome]. Ann Endocrinol (Paris), 1996; 57: 203-8.

303.     Manning PJ,Evans MC,Reid IR, Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf), 1992; 36: 229-34.

304.     Rizzato G,Montemurro L, Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J, 1993; 6: 116-9.